Effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy

doi:10.3969/j.issn.1006-7795.2018.04.022

Abstract

Abstract: Objective To investigate the effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy. Methods Eighty-four patients with advanced cervical cancer were admitted from February 2015 to March 2017, who were divided into single group and combination group by random digital table method, and there were 42 cases in each group. The single group was treated with taxinol plus platinum (TP) chemotherapy, while the combination group was treated with Guizhi Fuling decoction on the basis of the single group. The clinical effect was compared, and the peripheral blood samples of patients of the two groups before and after treatment were collected, then the levels of the serum immunoglobulin (IgG, IgA, IgM) and T lymphocyte subsets (CD3⁺, CD4⁺, CD8⁺, CD4⁺/CD8⁺) of the two groups were detected and compared, as well as the toxic and side reactions of patients. Results The grade distribution of the clinical effect between the two groups had a significant difference (P<0.05), and the clinical benefit rate (CBR) of the combination group was significantly higher than that of the single group (P<0.05). The levels of serum IgG, IgA, IgM, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ of the single group after treatment were significantly lower than those before treatment (P<0.05), and CD8⁺ of the single group after treatment was significantly higher than that before treatment (P<0.05), but the levels of serum IgG, IgA, IgM, CD3⁺, CD4⁺, CD8⁺ and CD4⁺/CD8⁺ of the combination group before treatment and after treatment showed no significant differences (P>0.05), and the levels of serum IgG, IgA, IgM, CD3⁺, CD4⁺ and CD4⁺/CD8⁺ of the combination group after treatment were significantly higher than those of the single group (P<0.05), but CD8+ was significantly lower than that of the single group (P<0.05). The incidence rates of bone marrow suppression, rectal irritation, skin reaction and bladder irritation of the combination group were significantly lower than those of the single group (P<0.05). Conclusion Guizhi Fuling decoction in the treatment of advanced cervical cancer patients with chemotherapy can significantly improve the clinical effect, maintain the stability of the body's immune function and reduce the incidence of toxic and side reactions.

Key words: Guizhi Fuling decoction, advanced cervical cancer, clinical efficacy, toxic and side reactions

CLC Number:

R287

Chang Zhonglian, Sheng Xiaobin, Shi Xinlan, Wei Wei. Effect of synergism and attenuation of Guizhi Fuling decoction in patients with advanced cervical cancer treated with chemotherapy[J]. Journal of Capital Medical University, 2018, 39(4): 596-601.

0
/ / Recommend

Add to citation manager EndNote|Reference Manager|ProCite|BibTeX|RefWorks

URL: https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/10.3969/j.issn.1006-7795.2018.04.022

https://journal03.magtech.org.cn/Jweb_sdykdxxb/EN/Y2018/V39/I4/596

References

[1] Niibe Y, Onda T, Matsuo K, et al. Phase Ⅱ study of concurrent chemoradiotheapy using nedaplatin for locally advanced uterine cervical carcinoma(KGROG0501):final results[J]. Anticancer Res, 2017, 37(12):6983-6988.
[2] 刘少晓, 程晓燕, 郑红枫,等. 紫杉醇联合顺铂新辅助治疗局部晚期宫颈癌的临床疗效及安全性评价[J]. 中国临床药理学杂志, 2015, 31(6):432-434.
[3] 南方, 陈春华. 中西医结合治疗宫颈癌30例的临床疗效研究[J]. 世界中西医结合杂志, 2015, 10(11):1586-1588.
[4] 覃业语, 韦知樱, 韩方璇. 扶正固本汤联合化疗治疗宫颈癌临床疗效及安全性分析[J]. 广州中医药大学学报, 2016, 33(3):321-324.
[5] 李克光, 杨百茀, 殷品之, 等. 金匮要略讲义[M].上海:上海科学技术出版社,1985:229.
[6] 明松林, 刘燕, 杨铁柱,等. 桂枝茯苓汤对乳腺癌细胞株线粒体凋亡途径相关蛋白和细胞周期的影响[J]. 中医药导报, 2015, 45(17):23-26.
[7] 张敏. 妇科肿瘤学[M]. 北京:科学技术文献出版社, 2013:56-57.
[8] 李佩文, 崔慧娟. 实用中西医结合肿瘤内科学[M]. 北京:中国中医药出版社, 2007:31-32.
[9] 杨英珍, 袁亚萍,吕银,等.宫颈癌同步放化疗患者抑郁状况及其影响因素[J].中华肿瘤防治杂志,2017,24(23):1619-1623.
[10] 刘淑荣, 廖革望.局部晚期宫颈癌化疗联合放疗最佳模式探讨[J].中华肿瘤防治杂志,2017,24(3):196-200.
[11] Yavas G, Yavas C, Inan G. Locally advanced squamous cell cervical cancer in a patient with septate uterus[J]. J Contemp Brachytherapy, 2017, 9(5):487-489.
[12] 权丽丽. 紫杉醇联合顺铂辅助治疗中晚期宫颈癌近期疗效与安全性的Meta分析[J]. 中国药房, 2015, 26(24):3389-3392.
[13] 简小兰, 蒋益兰, 曾瀚,等. 中医综合治疗对Ⅲ~Ⅳ期宫颈癌证候积分的影响[J]. 山东中医药大学学报, 2016, 40(6):514-517.
[14] 黄相艳. 桂枝茯苓丸加减配合西药治疗晚期卵巢癌患者临床疗效[J]. 陕西中医, 2017, 38(5):643-645.
[15] 李笠, 高树苓. 米非司酮联合桂枝茯苓胶囊治疗子宫肌瘤患者的疗效分析[J]. 中国肿瘤临床与康复, 2015, 22(1):62-65.
[16] 李文静, 李雪岩, 崔涛,等. 莪术-三棱药对合煎液对大鼠子宫肌瘤的防治作用及机制研究[J]. 中国药房, 2017, 28(19):2609-2612.
[17] Sharma M, Khan R, Aggarwal M, et al. Modulatory effects of chemoradiation on angiogenic factors and laminin in cervical cancer:link with treatment response[J]. Asian Pac J Cancer Prev, 2017, 18(11):2937-2944.
[18] 叶威静, 赵楚楚, 朱雪琼. 桂枝茯苓胶囊治疗子宫肌瘤疗效的研究进展[J]. 医学研究杂志, 2015, 44(11):15-17.
[19] 江益平, 吴秀, 李娜,等. 桂枝茯苓胶囊及其活性成分组合物免疫调节活性及其机制研究[J]. 中国中药杂志, 2015, 40(15):3068-3071.
[20] 刘亚玮, 毕丽鑫, 赵磊. 黄芪注射液辅助治疗耐多药肺结核的临床效果及对免疫功能的影响[J]. 现代医学, 2016, 18(4):462-466.
[21] 殷红岩, 杨娥, 梁江红,等. 桂枝茯苓丸干预裸鼠上皮性卵巢癌的机制研究[J]. 国际中医中药杂志, 2016, 38(9):831-836.
[22] 张珍珍, 张新庄, 李娜,等. 桂枝茯苓胶囊及其活性成分组合物抗炎作用与机制研究[J]. 中国中药杂志, 2015, 40(6):993-998.
[23] 尚伟庆. 黄芪当归合剂对肾病综合征患者肾功能、炎症机制及疗效的影响[J]. 中华中医药学刊, 2017, 35(5):1339-1341.